Gelernter Joel, Kranzler Henry R, Sherva Richard, Koesterer Ryan, Almasy Laura, Zhao Hongyu, Farrer Lindsay A
Department of Psychiatry, Division of Human Genetics, Departments of Genetics and Neurobiology, Yale University School of Medicine, VA Connecticut Healthcare Center, West Haven.
Philadelphia VA Medical Center, Philadelphia, Pennsylvania.
Biol Psychiatry. 2014 Jul 1;76(1):66-74. doi: 10.1016/j.biopsych.2013.08.034. Epub 2013 Oct 19.
We report a genome-wide association study (GWAS) of two populations, African-American and European-American (AA, EA) for opioid dependence (OD) in three sets of subjects, to identify pathways, genes, and alleles important in OD risk.
The design employed three phases (on the basis of separate sample collections). Phase 1 included our discovery GWAS dataset consisting of 5697 subjects (58% AA) diagnosed with opioid and/or other substance dependence and control subjects. Subjects were genotyped with the Illumina OmniQuad microarray, yielding 890,000 single nucleotide polymorphisms (SNPs) suitable for analysis. Additional genotypes were imputed with the 1000 Genomes reference panel. Top-ranked findings were further evaluated in Phase 2 by incorporating information from the publicly available Study of Addiction: Genetics and Environment dataset, with GWAS data from 4063 subjects (32% AA). In Phase 3, the most significant SNPs from Phase 2 were genotyped in 2549 independent subjects (32% AA). Analyses were performed with case-control and ordinal trait designs.
Most significant results emerged from the AA subgroup. Genome-wide-significant associations (p < 5.0 × 10(-8)) were observed with SNPs from multiple loci-KCNG2*rs62103177 was most significant after combining results from datasets in every phase of the study. The most compelling results were obtained with genes involved in potassium signaling pathways (e.g., KCNC1 and KCNG2). Pathway analysis also implicated genes involved in calcium signaling and long-term potentiation.
This is the first study to identify risk variants for OD with GWAS. Our results strongly implicate risk pathways and provide insights into novel therapeutic and prevention strategies and might biologically bridge OD and other non-substance dependence psychiatric traits where similar pathways have been implicated.
我们报告了一项针对非裔美国人和欧裔美国人(AA,EA)两个群体的全基因组关联研究(GWAS),该研究在三组受试者中针对阿片类药物依赖(OD)展开,以确定在OD风险中起重要作用的途径、基因和等位基因。
该设计采用三个阶段(基于单独的样本收集)。第一阶段包括我们的发现GWAS数据集,该数据集由5697名受试者(58%为AA)组成,这些受试者被诊断为阿片类药物和/或其他物质依赖以及对照受试者。受试者使用Illumina OmniQuad微阵列进行基因分型,产生了890,000个适合分析的单核苷酸多态性(SNP)。额外的基因型用千人基因组参考面板进行推算。在第二阶段,通过纳入来自公开可用的成瘾研究:遗传学与环境数据集的信息以及来自4063名受试者(32%为AA)的GWAS数据,对排名靠前的发现进行进一步评估。在第三阶段,对来自第二阶段的最显著SNP在2549名独立受试者(32%为AA)中进行基因分型。分析采用病例对照和有序性状设计。
最显著的结果出现在AA亚组中。在多个位点的SNP中观察到全基因组显著关联(p < 5.0 × 10⁻⁸)——在结合研究各阶段数据集的结果后,KCNG2*rs62103177最为显著。最引人注目的结果是在参与钾信号通路的基因(如KCNC1和KCNG2)中获得的。通路分析还涉及参与钙信号和长时程增强的基因。
这是第一项通过GWAS识别OD风险变异的研究。我们的结果有力地表明了风险途径,并为新的治疗和预防策略提供了见解,并且可能在生物学上连接OD和其他非物质依赖的精神特质,其中涉及类似的途径。